Taysha Gene Therapies (TSHA) Prepaid Assets (2020 - 2026)
Taysha Gene Therapies (TSHA) reported Prepaid Assets of $1.0 million for Q1 2026, up 335.78% on a YoY basis from $232000.0 in Q1 2025, and down 77.18% sequentially from $4.4 million in Q4 2025.
Taysha Gene Therapies (TSHA) Prepaid Assets (2020 - 2026) Analysis & Trends
Taysha Gene Therapies (TSHA) has 7 years of Prepaid Assets data on file, last reported at $1.0 million in Q1 2026.
- For the quarter ending Q1 2026, Prepaid Assets rose 335.78% year-over-year to $1.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.0 million (up 335.78% YoY), and the FY2025 full-year result was $4.4 million, up 67.52% from the prior year.
- Prepaid Assets slipped to $1.0 million in Q1 2026, from $4.4 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $4.4 million in Q4 2025 to a low of $74000.0 in Q3 2022.
- A 5-year average of $930470.6 and a median of $404000.0 in 2023 frame the typical range for Prepaid Assets.
- Across the five-year window, Prepaid Assets plunged 98.91% in 2022 and soared 1750.91% in 2025, its largest moves.
- Tracing TSHA's Prepaid Assets over 5 years: stood at $388000.0 in 2022, then fell by 24.74% to $292000.0 in 2023, then surged by 805.82% to $2.6 million in 2024, then soared by 67.52% to $4.4 million in 2025, then plunged by 77.18% to $1.0 million in 2026.
- Business Quant data shows TSHA's Prepaid Assets at $1.0 million in Q1 2026, $4.4 million in Q4 2025, and $456000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Taysha Gene Therapies | 2.14 Bn | 2.14 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.01 Mn |
| Dec 31, 2025 | 4.43 Mn |
| Sep 30, 2025 | 456,000.00 |
| Jun 30, 2025 | 3.05 Mn |
| Mar 31, 2025 | 232,000.00 |
| Dec 31, 2024 | 2.65 Mn |
| Sep 30, 2024 | 465,000.00 |
| Jun 30, 2024 | 165,000.00 |
| Mar 31, 2024 | 269,000.00 |
| Dec 31, 2023 | 292,000.00 |
| Sep 30, 2023 | 404,000.00 |
| Jun 30, 2023 | 510,000.00 |
| Mar 31, 2023 | 373,000.00 |
| Dec 31, 2022 | 388,000.00 |
| Sep 30, 2022 | 74,000.00 |
| Jun 30, 2022 | 108,000.00 |
| Mar 31, 2022 | 941,000.00 |
| Dec 31, 2021 | 863,000.00 |
| Sep 30, 2021 | 144,000.00 |
| Jun 30, 2021 | 9.93 Mn |